Advocacy intelligence hub — real-time data for patient organizations
Jose Ivan Rodriguez de Molina Serrano — NA
National Cancer Institute (NCI) — PHASE2
Assiut University
The Cooper Health System — PHASE1, PHASE2
The University of Hong Kong — NA
Qilu Hospital of Shandong University
Northumbria University — NA
Tanta University — PHASE2
Shenyang Northern Hospital — PHASE4
Harran University — NA
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs2
Orencia
Bristol-Myers Squibb Co.
Ryoncil
Mesoblast, Inc.
Ryoncil
(remestemcel-L-rknd)Orphan drugMesoblast, Inc.
12.1 Mechanism of Action The mechanism of action for RYONCIL is not clear but may be related to immunomodulatory effects. Data from in vitro studies d...
JAKAFI
(RUXOLITINIB)Orphan drugstandardIncyte Corporation
Gautam Borthakur, M.D
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Kyoo H. Lee, MD
Asan Medical Center
Elias Jabbour, M.D
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Christian Meyer, MD
Translational Research Institute for Metabolism and Diabetes
Allen Eng Juh Yeoh, MBBS
Professor
Tal Hasin, MD, MD
Medical corps, Israel Defence Forces
📍 ROCHESTER, MN